Immunic, Inc.
NASDAQ:IMUXBiotechnology
-$0.04 today
- Market cap
- $102.61M
- Beta
- 1.39
- P/E (TTM)
- -4.1
- EPS (TTM)
- -$3.46
Volume 0.17M
Average 0.27M
IMUX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Immunic, Inc.NASDAQ: IMUX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$32.56M, compared with -$25.43M a year earlier. Trailing-twelve-month EBITDA was -$104.13M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +3.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$32.56M-69.0% QoQ
- Last fiscal yearDec 2025
- -$97M+3.4% YoY
- LTMMar 2026
- -$104.13M-8.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -28.0% | +100.0% | +128.0 pp |
| 1 year | +3.4% | +100.0% | +96.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (97M) USD
- Year-over-year change
- +3.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (97M) | +3.4% |
| FY2024 | 2024-12-31 | (100.37M) | -7.3% |
| FY2023 | 2023-12-31 | (93.5M) | -8.2% |
| FY2022 | 2022-12-31 | (86.44M) | +6.9% |
| FY2021 | 2021-12-31 | (92.86M) | — |
EBITDA vs competitors
How IMUX compares with its peers on the latest reported figures
- IMUX's LTM Mar 2026 EBITDA of -$104.13M is the 8th highest of the 9 companies compared; the peer median is -$70.25M.
- Its year-over-year change of -8.2% is the 8th highest of 9, against a peer median of +6.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.3M | +203.4% | — | 18.5% | |
| LTM Mar 2026 | -$46.12M | +63.6% | — | — | |
| LTM Mar 2026 | -$58.88M | -297.6% | — | — | |
CBUSCibus, Inc. | LTM Mar 2026 | -$62.31M | +76.4% | — | 1453.8% |
| LTM Mar 2026 | -$78.19M | +0.2% | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$82.08M | +0.7% | — | — |
| LTM Mar 2026 | -$102.73M | +7.3% | — | — | |
| LTM Mar 2026 | -$104.13M | -8.2% | — | — | |
| LTM Mar 2026 | -$118.65M | +4.8% | — | 1298.7% | |
| Peer median (excluding IMUX) | -$70.25M | +6.0% | — | 1298.7% | |
Competitors are the stored peer set for IMUX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 61.12M | 71.26M | 83.22M | 80.05M | 81.98M |
| Selling, General & Admin | 13.3M | 15.26M | 16.01M | 18.01M | 21.25M |
| Operating Expenses | 91.67M | 119.49M | 99.22M | 98.05M | 103.23M |
| Depreciation & Amortization | 85K | 77K | 111K | 134K | 168K |
| EBITDA | (92.86M) | (86.44M) | (93.5M) | (100.37M) | (97M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (91.67M) | (119.49M) | (99.22M) | (98.05M) | (103.23M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 66K | 1.04M | 3.08M | 3.39M | 1.04M |
| Interest Expense | 0 | 1.04M | 0 | 0 | 0 |
| Other Income / Expenses | (1.28M) | (919K) | 5.61M | (2.46M) | 6.06M |
| Income Before Tax | (92.95M) | (120.41M) | (93.61M) | (100.51M) | (97.17M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (92.95M) | (120.41M) | (93.61M) | (100.51M) | (97.17M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (39.20) | (37.80) | (21.10) | (10.00) | (6.24) |
| EPS (Diluted) | (39.20) | (37.80) | (21.10) | (10.00) | (6.24) |
| Weighted Avg Shares | 2.37M | 3.18M | 4.43M | 10.02M | 15.57M |
| Weighted Avg Shares (Diluted) | 2.37M | 3.18M | 4.43M | 10.02M | 15.57M |
Immunic, Inc.
NASDAQ:IMUX
Intrinsic Alpha fair value
Locked
Current Price
$7.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.